HIV Treatment: How Personalized Medicine is Making a Difference

In 2019, there were approximately 38 million people worldwide living with HIV, a condition that once almost certainly meant a death sentence. Thanks to advancements in combination antiretroviral therapy (cART), people with HIV can now manage their condition and live nearly as long as their non-infected peers. However, the journey towards a universally effective HIV treatment is far from over. The emergence of personalized medicine has brought new opportunities to optimize treatment regimens for individual patients based on their unique genetic and physiological profiles. This article delves into the current status of personalized medicine in HIV treatment and how it may herald a future where every patient receives a treatment regimen tailored specifically to their unique physiology and disease progression.

Image Source: Pexels

The Evolution of HIV Treatment

The standard of care for HIV has evolved significantly over the past few decades. In the early days of the epidemic, treatment options were limited and largely ineffective. The introduction of cART in the late 1990s dramatically changed the landscape of HIV treatment, turning a once fatal diagnosis into a manageable chronic condition.

cART involves a combination of three or more antiretroviral drugs from different classes, each designed to interrupt the HIV life cycle at different stages, thereby preventing the virus from replicating. This multi-drug approach helps to suppress viral loads, restore immune function, and reduce the risk of developing drug resistance.

Over the years, more than two dozen antiretroviral drugs have been approved by the FDA, falling into several different categories, including CD4-directed post-attachment inhibitors, chemokine receptor antagonists (CRAs), fusion inhibitors (FIs), nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleotide reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (IIs), protease inhibitors (PIs), and pharmacokinetic enhancers. The availability of so many treatment options has made it possible to tailor cART regimens to the specific needs of individual patients.

The Challenge of HIV Latency

Despite the effectiveness of cART, HIV remains a chronic condition due to the phenomenon of viral latency. HIV latency refers to the ability of the virus to persist in a dormant state within certain cells, primarily resting memory CD4+ T cells, even in the presence of antiretroviral therapy. These latent viral reservoirs can reactivate and begin producing new viruses if treatment is interrupted, posing a significant barrier to curing the disease.

Various strategies have been explored to eliminate these latent reservoirs, including the “shock and kill” approach, which aims to reactivate the latent virus and then eliminate the infected cells. However, these strategies have not yet resulted in a complete eradication of the virus. Therefore, individuals with HIV must continue taking antiretroviral therapy for life.

The Promise of Personalized Medicine

The concept of personalized medicine, or precision medicine, holds great promise for improving HIV treatment outcomes. Personalized medicine involves tailoring treatment to the unique genetic and physiological characteristics of each individual patient. In the context of HIV treatment, this could involve selecting specific antiretroviral drugs and dosing regimens based on a patient’s genetic profile, the specific strain of HIV they are infected with, and their overall health status.

The advent of high-throughput omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, has made it possible to generate vast amounts of data on individual patients. These data can provide insights into the genetic and physiological factors that influence an individual’s response to antiretroviral therapy, including their risk of developing drug resistance or experiencing adverse drug reactions.

However, simply having access to these data is not enough. Advanced computational methods, including machine learning and systems biology, are needed to analyze these complex datasets and identify patterns that can guide personalized treatment decisions.

The Role of Systems Biology in Personalized Medicine

Systems biology is a field of study that uses mathematical modeling and computational methods to understand complex biological systems. In the context of personalized medicine, systems biology can be used to develop computational models of disease processes that can predict an individual’s response to different treatment regimens.

These models can incorporate data on a wide range of factors that influence disease progression and treatment response, including genetic variations, physiological parameters, environmental exposures, and lifestyle factors. By simulating the dynamics of disease processes and treatment interventions, these models can help identify the most effective treatment strategies for individual patients.

One of the key challenges in developing these models is estimating the parameters that define the model, such as the rate of viral replication or the potency of an antiretroviral drug. These parameters often vary between individuals, and accurate estimation of these parameters is critical for making accurate predictions. Despite these challenges, advancements in computational methods and increasing availability of high-quality patient data are making it increasingly feasible to develop personalized disease models.

The Potential of Personalized Medicine for HIV Treatment

Several recent studies have demonstrated the potential of personalized medicine approaches for optimizing HIV treatment. For example, a study by Mu et al. highlighted the potential utility of therapeutic drug monitoring (TDM) for personalizing antiretroviral therapy. TDM involves measuring the concentrations of antiretroviral drugs in a patient’s blood to ensure they are within the therapeutic range.

Mu et al. suggested that TDM could be particularly useful in certain high-risk patient populations, such as pregnant women, patients who are not responding to therapy, and those with suspected drug-drug or drug-food interactions. The authors provided an example of how genetic testing could be used in conjunction with TDM to predict a patient’s response to a specific antiretroviral drug. In their study, they found that patients with certain genetic variants were significantly less likely to experience treatment failure with a combination of lopinavir and ritonavir.

Another study by Lengauer et al. explored the potential of using computational models to predict the development of drug resistance in HIV. The authors noted that the ability to predict which patients are likely to develop resistance to specific antiretroviral drugs could greatly enhance the effectiveness of personalized HIV treatment strategies.

These studies illustrate the potential of personalized medicine approaches for optimizing HIV treatment. However, many challenges remain, and further research is needed to refine these approaches and evaluate their effectiveness in real-world clinical settings.

The Future of Personalized Medicine in HIV Treatment

The field of personalized medicine is still in its early stages, and much work remains to be done to realize its full potential in the context of HIV treatment. Key challenges include the need for more comprehensive and accurate patient data, the development of more sophisticated computational models, and the need to validate these models in clinical trials.

In addition, there are significant logistical and ethical challenges associated with the implementation of personalized medicine. These include the cost and complexity of genetic testing and other omics technologies, issues related to data privacy and consent, and the need to ensure that personalized medicine approaches are accessible and beneficial to all patients, regardless of their socioeconomic status or geographic location.

Despite these challenges, the promise of personalized medicine for HIV treatment is clear. By tailoring treatment to the unique genetic and physiological characteristics of each individual patient, it may be possible to improve treatment outcomes, reduce the risk of drug resistance, and minimize adverse drug reactions. As our understanding of the complex interplay between host genetics, viral genetics, and treatment response continues to grow, personalized medicine is poised to play an increasingly important role in the fight against HIV.

Conclusion

The era of personalized medicine heralds a future where every patient with HIV receives a treatment regimen tailored specifically to their unique physiology and disease progression. While the journey towards universally effective HIV treatment is far from over, the emergence of personalized medicine has brought forth new opportunities to optimize treatment regimens for individual patients. The road ahead is challenging, but the promise of a future where every patient with HIV has the best possible chance of living a long, healthy life makes the journey worth it.

Acknowledgements

The authors would like to extend their gratitude to Richard Voit, MD-PhD for his constructive feedback and careful editing of this article. This work was supported in part by grant NIH-2P30ES019776-05 (PI: Carmen Marsit) and by the Georgia Research Alliance. The funding agency is not responsible for the content of this article.

References

  1. HIV.org. HIV and AIDS Information: U.S. Statistics. 2021. Accessed from:https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics.
  2. Fauci AS, Lane HC. Four decades of HIV/AIDS–much accomplished, much to do. New England Journal of Medicine. 2020. Jul 2;383(1):1-4.PubMed
  3. Mu Y, Kodidela S, Wang Y, Kumar S, Cory TJ. The dawn of precision medicine in HIV: state of the art of pharmacotherapy. Expert Opinion on Pharmacotherapy. 2018. Sep 22;19(14):1581-95.PubMed
  4. Boskey E. What Is cART? 2021. Accessed from:https://www.verywellhealth.com/what-is-cart-p2-3132623.
  5. Tseng A, Seet J, Phillips E. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. British Journal of Clinical Pharmacology. 2015. Feb;79(2):182-94.PubMed
  6. Kaplan JE. Antiretrovirals: HIV and AIDS Drug. WebMD. 2020.
  7. Rivera DM. Pediatric HIV infection medication. MedScape. 2021. Accessed from:https://emedicine.medscape.com/article/965086-medication#7.
  8. Feng Q, Zhou A, Zou H, Ingle S, May MT, Cai W, Cheng CY, Yang Z, Tang J. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019. Jul 8;366.PubMed
  9. Dufour C, Gantner P, Fromentin R, Chomont N. The multifaceted nature of HIV latency. The Journal of Clinical Investigation. 2021. May 28;130(7):3381-3390.PubMed
  10. Dahabieh MS, Battivelli E, Verdin E. Understanding HIV latency: the road to an HIV cure. Annual Review of Medicine. 2015. Jan 14;66:407-21.PubMed
  11. Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology. 2013. Dec;10(1):1-1.PubMed
  12. Elsheikh MM, Tang Y, Li D, Jiang G. Deep latency: A new insight into a functional HIV cure. EBioMedicine. 2019. Jul 1;45:624-9.PubMed
  13. Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C. HIV. Lancet. 2018. Aug 25;392(10148):685-697.PubMed
  14. Kitano H. Computational systems biology. Nature. 2002. Nov;420(6912):206-10.PubMed
  15. Voit EO. The role of systems biology in predictive health and personalized medicine. The Open Pathology Journal. 2008. Jun 26;2(1).Google Scholar]
  16. Davis JD, Kumbale CM, Zhang Q, Voit EO. Dynamical systems approaches to personalized medicine. Current Opinion in Biotechnology. 2019. Aug 1;58:168-74.PubMed
  17. Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, O’Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Advances. 2018. Jun 26;2(12):1449-58.PubMed
  18. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. New England Journal of Medicine. 2004. Aug 5;351(6):533-42.PubMed
  19. Foubister V. Genes predict childhood leukemia outcome. Drug Discovery Today. 2005;12(10):812.PubMed
  20. Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol Syst Biol. 2009;5:249.PubMed
  21. Voit EO. Overview of Networks and Systems. In: Wolkenhauer O. Systems Medicine: Integrative, Qualitative and Computational Approaches. Academic Press; 2020. Aug 24.Google Scholar]
  22. Voit EO, Brigham KL. The role of systems biology in predictive health and personalized medicine. The Open Pathology Journal. 2008. Jun 26;2(1).Google Scholar]
  23. Costello Z, Martin HG. A machine learning approach to predict metabolic pathway dynamics from time-series multiomics data. NPJ Systems Biology and Applications. 2018. May 29;4(1):1-4.PubMed
  24. Kumbale C, Davis JD, Voit EO. Models for Personalized Medicine. In: Wolkenhauer O. Systems Medicine: Integrative, Qualitative and Computational Approaches. Academic Press; 2020. Aug 24; 306-317.Google Scholar]
  25. Marin-Sanguino A, Gupta SK, Voit EO, Vera J. Biochemical pathway modeling tools for drug target detection in cancer and other complex diseases. Methods in Enzymology. 2011. Jan 1;487:319-69.PubMed
  26. Voit EO. Systems Biology: A Very Short Introduction. Oxford University Press; 2020. Mar 26.Google Scholar]
  27. Voit EO. Models-of-data and models-of-processes in the post-genomic era. Mathematical Biosciences. 2002. Nov 1;180(1-2):263-74.PubMed
  28. Prague M, Commenges D, Thiebaut R. Dynamical models of biomarkers and clinical progression for personalized medicine: The HIV context. Advanced Drug Delivery Reviews. 2013. Jun 30;65(7):954-65.PubMed
  29. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995. Jan;373(6510):117-22.PubMed
  30. Chou IC, Voit EO. Recent developments in parameter estimation and structure identification of biochemical and genomic systems. Mathematical Biosciences. 2009. Jun 1;219(2):57-83.PubMed
  31. Lengauer T, Pfeifer N, Kaiser R. Personalized HIV therapy to control drug resistance. Drug Discovery Today: Technologies. 2014. Mar 1;11:57-64.PubMed
  32. Berno G, Zaccarelli M, Gori C, Tempestilli M, Pucci L, Antinori A, Perno CF, Paolo Pucillo L, D’Arrigo R. Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients. Journal of the International AIDS Society. 2014. Nov;17:19589.PubMed
  33. Visentin R, Campos-Nañez E, Schiavon M, Lv D, Vettoretti M, Breton M, Kovatchev BP, Dalla Man C, Cobelli C. The UVA/Padova type 1 diabetes simulator goes from single meal to single day. Journal of Diabetes Science and Technology. 2018. Mar;12(2):273-81.PubMed

Privacy Policy

Terms of Use

Blog

Heart-to-Heart